World Hemophilia Market Analysis by Koncept Analytics Recently Published at

05 Jul 2012 • by Natalie Aster

LONDON – The global market for hemophilia products has shown continuous growth in the past years growing at 8.96% CAGR from 2006 to 2011 and is projected to expand steadily in the upcoming years.

The major factors driving the growth of the industry are the increasing number of new patients registering themselves for treatment at the hospitals and other healthcare institutions, growing male population, rising expenditure on healthcare globally, and the increased life expectancy for hemophilia patients. At the same time factors like antibody neutralization and lack of diagnostic facilities leading to improper or late detection of the disease are posing acute challenges in front of every other person falling within the realm of this therapeutic field.

New study “Global Hemophilia Market Report: 2012 Edition” developed by Koncept Analytics has been recently published by Market Publishers Ltd.

Report Details:

Title: Global Hemophilia Market Report: 2012 Edition
Published: June, 2012
Pages: 47
Price: US$ 800.00

The report offers an in-depth analysis of the global hemophilia treatment market, discussing the major trends, growth drivers and potential markets. It examines the competitive landscape of the industry and profiles top market players with an insight into their key financials and business strategies. Furthermore, the potential future growth path of the global hemophilia treatment market is also discussed in detail.

Major companies profiled include: Novo Nordisk, Baxter International, Grifols, and Pfizer, Inc.

More new market research reports by the publisher can be found at Koncept Analytics page.



The Market Publishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970